Venture Capital Journal · 26 December 2023 · by Krish Ramadurai, then a Partner at Harmonix
In an op-ed for Venture Capital Journal, Krish Ramadurai argued that Europe’s biotech and deep tech companies are held back less by a shortage of good science than by a shortage of growth capital to scale it at home. Without that funding, he wrote, the value created by European research is increasingly captured elsewhere.
“Without additional deep tech growth capital, Europe risks standing on the sidelines as other countries harvest its fruits of innovation.”
Krish Ramadurai, Venture Capital Journal
Read the full article at Venture Capital Journal → (subscription required)